Hospital laboratory reporting may be a barrier to detection of 'microsize' myocardial infarction in the US: An observational study

BMC Health Services Research

Volumn 13, Issue 1, 2013, Pages

  Safford, Monika M ^a   Parmar, Gaurav ^a   Barasch, Codrin S ^a   Halanych, Jewell H ^a   Glasser, Stephen P ^a   Goff, David C ^b   Prineas, Ronald J ^c   Brown, Todd M ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndrome; Quality control; Troponin

Indexed keywords

BIOLOGICAL MARKER; TROPONIN;

AGED; ARTICLE; ETHNOLOGY; FEMALE; HEART INFARCTION; HOSPITAL LABORATORY; HOSPITALIZATION; HUMAN; MALE; MORTALITY; RISK ASSESSMENT; STANDARD; STATISTICAL MODEL; STATISTICS; UNITED STATES;

AGED; BIOLOGICAL MARKERS; FEMALE; HOSPITALIZATION; HUMANS; LABORATORIES, HOSPITAL; LOGISTIC MODELS; MALE; MYOCARDIAL INFARCTION; REFERENCE STANDARDS; RISK ASSESSMENT; TROPONIN; UNITED STATES;

MLCS; MLOWN;

EID: 84876796175     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-13-162     Document Type: Article

References (33)

1. Universal definition of myocardial infarction. Thygesen K, Alpert JS, White HD, J Am Coll Cardiol 2007 50 22 2173 2195 10.1016/j.jacc.2007.09.011 18036459 (Pubitemid 350123680)
2. Universal definition of myocardial infarction. Thygesen K, Alpert JS, White HD, Eur Heart J 2007 28 20 2525 2538 17951287 (Pubitemid 47616190)
3. Universal definition of myocardial infarction. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Circulation 2007 116 22 2634 2653 10.1161/CIRCULATIONAHA.107.187397 17951284 (Pubitemid 350182388)
4. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: A statement from the AHA Council on Epidemiology and Prevention, AHA Statistics Committee, World Heart Federation Council on Epidemiology and Prevention, European Society of Cardiology Working Group on Epidemiology and Prevention, Centers for Disease Control and Prevention, and the National Heart Lung and Blood Institute. Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D, Goldberg RJ, Hand MM, Jaffe AS, Julian DG, Circulation 2003 108 20 2543 2549 10.1161/01.CIR.0000100560.46946.EA 14610011 (Pubitemid 37451755)
5. New definition of myocardial infarction: impact on long-term mortality. Hochholzer W, Buettner HJ, Trenk D, Laule K, Christ M, Neumann FJ, Mueller C, Am J Med 2008 121 5 399 405 10.1016/j.amjmed.2008.01.033 18456036 (Pubitemid 351626008)
6. Prognostic value of quantitative troponin T measurements in unstable angina/non-ST-segment elevation acute myocardial infarction treated early and predominantly with percutaneous coronary intervention. Mueller C, Neumann FJ, Perruchoud AP, Zeller T, Buettner HJ, Am J Med 2004 117 12 897 902 10.1016/j.amjmed.2004.06.043 15629727 (Pubitemid 40075556)
7. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O'Hanesian MA, Wagner GS, Kleiman NS, Harrell FE Jr, N Engl J Med 1996 335 18 1333 1341 10.1056/NEJM199610313351801 8857016 (Pubitemid 26360451)
8. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, N Engl J Med 1996 335 18 1342 1349 10.1056/NEJM199610313351802 8857017 (Pubitemid 26360452)
9. Delivery of preventive services to older adults by primary care physicians. Pham HH, Schrag D, Hargraves JL, Bach PB, JAMA 2005 294 4 473 481 10.1001/jama.294.4.473 16046654 (Pubitemid 41124180)
10. Redefining myocardial infarction for the 21st century. Alpert JS, Malasky BR, Thygesen K, Trans Am Clin Climatol Assoc 2004 115 79 96 17060958
11. A call for universal definitions in cardiovascular disease. Alpert JS, Thygesen K, Circulation 2006 114 8 757 758 10.1161/CIRCULATIONAHA.106.648030 16923767 (Pubitemid 44268225)
12. A new global definition of myocardial infarction for the 21st century. Alpert JS, Thygesen K, Pol Arch Med Wewn 2007 117 11-12 485 486 18363245 (Pubitemid 351169846)
13. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Alpert JS, Thygesen K, Antman E, Bassand JP, J Am Coll Cardiol 2000 36 3 959 969 10.1016/S0735-1097(00)00804-4 10987628
14. The universal definition of myocardial infarction: a consensus document: ischaemic heart disease. Alpert JS, Thygesen K, Jaffe A, White HD, Heart 2008 94 10 1335 1341 18801791
15. International federation of Clinical Chemistry and Laboratory Medicine. Analytic characteristics of commerical cardiac troponin I and T assays as stated by manufacturer (version October 2008) 2013 http://www.ifcc.org/media/102202/ IFCC-Troponin-Table-vDec-2010-FINAL-ug-L-28Jan11.pdf, accessed May 6
16. Population trends in the incidence and outcomes of acute myocardial infarction. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS, N Engl J Med 2010 362 23 2155 2165 10.1056/NEJMoa0908610 20558366
17. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ, Am J Med 2011 124 1 40 47 10.1016/j.amjmed.2010.07.023 21187184
18. The reasons for geographic and racial differences in stroke study: objectives and design. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, Graham A, Moy CS, Howard G, Neuroepidemiology 2005 25 3 135 143 10.1159/000086678 15990444 (Pubitemid 41207066)
19. International Federation of Clinical Chemistry and Laboratory Medicine. C-SMCD Cardiac Troponin Assays 2013 http://www.ifcc.org/media/102199/IFCC- Troponin-Table-vDec-2010-FINAL-ng-L-28Jan11.pdf, accessed May 6
20. Evidence-based decision limits for cardiac troponin: low-level elevation and prognosis. Morrow DA, Am Heart J 2004 148 5 739 742 10.1016/j.ahj.2004.05. 024 15523301
21. Impact of changing definitions for myocardial infarction: a report from the AMIS registry. Urban P, Radovanovic D, Erne P, Stauffer JC, Pedrazzini G, Windecker S, Bertel O, Am J Med 2008 121 12 1065 1071 10.1016/j.amjmed.2008.08. 020 19028202
22. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. Mills NL, Churchhouse AM, Lee KK, Anand A, Gamble D, Shah AS, Paterson E, MacLeod M, Graham C, Walker S, JAMA 2011 305 12 1210 1216 10.1001/jama.2011.338 21427373
23. Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality. Eggers KM, Lagerqvist B, Venge P, Wallentin L, Lindahl B, Circulation 2007 116 17 1907 1914 10.1161/CIRCULATIONAHA.107.708529 17909103 (Pubitemid 350287086)
24. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Zethelius B, Johnston N, Venge P, Circulation 2006 113 8 1071 1078 10.1161/CIRCULATIONAHA.105.570762 16490824
25. A model for troponin I as a quantitative predictor of in-hospital mortality. Waxman DA, Hecht S, Schappert J, Husk G, J Am Coll Cardiol 2006 48 9 1755 1762 10.1016/j.jacc.2006.05.075 17084245 (Pubitemid 44648620)
26. Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. Newby LK, Alpert JS, Ohman EM, Thygesen K, Califf RM, Am Heart J 2002 144 6 957 980 10.1067/mhj.2002.129778 12486420 (Pubitemid 36026909)
27. Accountability Measaures. A New Concept to Promote Quality Improvement 2013 http://www.jointcommission.org/accountability-measures.aspx, accessed May 6
28. Premier Hospital Quality Incentive Demonstration 2013 http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/ HospitalQualityInits/index.html?redirect=/hospitalqualityinits, accessed May 6
29. CDC Wonder Compressed Mortality File [ http://wonder.cdc.gov/mortsql.html ]
30. Initial phase of chronic medication use; patients' reasons for discontinuation. Hugtenburg JG, Blom AT, Kisoensingh SU, Br J Clin Pharmacol 2006 61 3 352 354 10.1111/j.1365-2125.2005.02569.x 16487231 (Pubitemid 43382637)
31. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Circulation 2006 113 24 2803 2809 10.1161/CIRCULATIONAHA.106.618066 16769908 (Pubitemid 44305292)
32. Impact of medication therapy discontinuation on mortality after myocardial infarction. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS, Arch Intern Med 2006 166 17 1842 1847 10.1001/archinte.166.17.1842 17000940 (Pubitemid 44455166)
33. Use of guidelines-recommended management and outcomes among women and men with low-level troponin elevation. Halim SA, Mulgund J, Chen AY, Matthew TR, Peterson ED, Gibler WB, Ohman EM, Newby LK, Circ Cardiovasc Qual Outcomes 2009 2 3 199 206 10.1161/CIRCOUTCOMES.108.810127 20031838